New hope for Hard-to-Treat breast cancer: drug combo trial launches
NCT ID NCT06954480
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests whether adding durvalumab to datopotamab deruxtecan helps people with a type of advanced breast cancer called PDL1-negative triple-negative breast cancer. About 140 women will be randomly assigned to get either the drug combination or the single drug alone. The goal is to see if the combination slows cancer growth better than the single drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts Cancer Institute, Centre of Experimental Cancer Medicine
NOT_YET_RECRUITINGLondon, EC1M 6BQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Barts Health NHS Trust
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.